Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 43 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,108,000 | -21.2% | 38,835 | -6.7% | 0.03% | -23.3% |
| Q2 2021 | $1,406,000 | +47.8% | 41,609 | +32.3% | 0.04% | +34.4% |
| Q1 2021 | $951,000 | -38.9% | 31,439 | 0.0% | 0.03% | -49.2% |
| Q4 2020 | $1,557,000 | +33.3% | 31,439 | +3.3% | 0.06% | +8.6% |
| Q3 2020 | $1,168,000 | -16.7% | 30,435 | -6.3% | 0.06% | -21.6% |
| Q2 2020 | $1,402,000 | +20.3% | 32,465 | -27.3% | 0.07% | -2.6% |
| Q1 2020 | $1,165,000 | -22.0% | 44,642 | -6.6% | 0.08% | -18.3% |
| Q4 2019 | $1,494,000 | -11.2% | 47,810 | -26.0% | 0.09% | -36.7% |
| Q3 2019 | $1,683,000 | +10.8% | 64,571 | -2.8% | 0.15% | +20.5% |
| Q2 2019 | $1,519,000 | -19.4% | 66,416 | -7.6% | 0.12% | +19.6% |
| Q1 2019 | $1,884,000 | +24.8% | 71,866 | -3.2% | 0.10% | +20.0% |
| Q4 2018 | $1,510,000 | – | 74,221 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |